Literature DB >> 16181819

The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF).

Mihai Gheorghiade1, Wendy Gattis Stough, Kirkwood F Adams, Allan S Jaffe, Victor Hasselblad, Christopher M O'Connor.   

Abstract

Acute heart failure syndromes (AHFS) are related to several diseases affecting not only the heart but also the kidneys and blood vessels. Emerging evidence indicates that myocardial injury may also play a role in the pathophysiology of AHFS, as suggested by increased levels of markers of injury, such as cardiac troponin (cTn). Although cTn is a known prognostic marker, the release of cTn during hospitalization has not been evaluated prospectively with serial measures. We prospectively evaluated patterns of cTn release by conducting serial measures of cTnI and cTnT in patients hospitalized for AHFS. This study enrolled 51 patients with AHFS who were admitted with worsening heart failure (HF) and a history of coronary artery disease (CAD) in whom an acute coronary event was not suspected. Levels of cTnI and cTnT were measured at 8, 32, 56, and 80 hours after study entry. At baseline, 73.9% of patients had detectable cTnI, and 43.5% had detectable cTnT levels. The median concentrations of cTnI and cTnT were unchanged from 0 to 32 hours, increased from 32 to 56 hours, then either plateaued (cTnT) or decreased to baseline (cTnI). Of the 26 patients who had no detectable cTn levels at baseline, 2 (7.7%) developed detectable cTnT and 5 (41.7%) developed detectable cTnI release during hospitalization. Detectable levels of cTn at baseline were related to short-term clinical events. In this study of patients with CAD in whom an acute coronary event was not suspected, most had detectable levels of cTn present at admission, and some patients developed cTn release during hospitalization. Because cTn release may be a marker for myocardial injury, this study raises the possibility that injury occurred in most patients admitted with AHFS. Therefore, the goal of therapy for AHFS should be not only to improve symptoms and hemodynamics but also to salvage myocardium. Accordingly, therapies for AHFS that are aimed at improving hemodynamics may affect long-term prognosis by either injuring or salvaging myocardium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181819     DOI: 10.1016/j.amjcard.2005.07.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

Review 2.  Perspective on the clinical application of troponin in heart failure and states of cardiac injury.

Authors:  Almasa Bass; J Herbert Patterson; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2009-04-05       Impact factor: 4.214

Review 3.  Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Andrew Ambrosy; Michael Böhm; Umberto Campia; John G F Cleland; Francesco Fedele; Gregg C Fonarow; Aldo P Maggioni; Alexandre Mebazaa; Mandeep Mehra; Marco Metra; Savina Nodari; Peter S Pang; Piotr Ponikowski; Hani N Sabbah; Michel Komajda; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

4.  Role of Cardiac Troponin Levels in Acute Heart Failure.

Authors:  Nicholas Wettersten; Alan Maisel
Journal:  Card Fail Rev       Date:  2015-10

Review 5.  [Therapeutic strategies in acute decompensated heart failure and cardiogenic shock].

Authors:  M Buerke; H Lemm; M Russ; A Schlitt; K Werdan
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

6.  Cardiac troponin I as prognostic marker in heart failure patients discharged from emergency department.

Authors:  Nicola Parenti; Silvia Bartolacci; Flavia Carle; Fanciulli Angelo
Journal:  Intern Emerg Med       Date:  2008-02-14       Impact factor: 3.397

Review 7.  Acute heart failure: patient characteristics and pathophysiology.

Authors:  Catherine N Marti; Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 8.  Identifying and Managing Hibernating Myocardium: What's New and What Remains Unknown?

Authors:  Matthew J Ryan; Divaka Perera
Journal:  Curr Heart Fail Rep       Date:  2018-08

9.  Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target.

Authors:  Marta Reina-Couto; Carolina Silva-Pereira; Patrícia Pereira-Terra; Janete Quelhas-Santos; João Bessa; Paula Serrão; Joana Afonso; Sandra Martins; Cláudia Camila Dias; Manuela Morato; João T Guimarães; Roberto Roncon-Albuquerque; José-Artur Paiva; António Albino-Teixeira; Teresa Sousa
Journal:  Front Physiol       Date:  2022-08-11       Impact factor: 4.755

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.